K Number
K200720
Device Name
D-Stat Radial Topical Hemostat
Date Cleared
2020-06-26

(99 days)

Product Code
Regulation Number
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The D-Stat Radial Topical Hemostat is applied topically and is indicated for the control of surface bleeding from vascular access sites and percutaneous catheters or tubes.
Device Description
D-Stat Radial topical hemostat (D-Stat Radial) is a hemostatic band consisting of an application device containing a lyophilized pad consisting of thrombin, sodium carboxylmethylcellulose and calcium chloride in a nonwoven gauze, and an adjustable retention strap and attached foam pads. Hemostasis is achieved by the physiological coagulation-inducing properties of the lyophilized pad combined with the compression delivered by the application device. The D-Stat Radial has been sterilized with irradiation.
More Information

No
The device description focuses on the physiological and mechanical properties of the hemostatic band and does not mention any computational or algorithmic components. The "Mentions AI, DNN, or ML" section explicitly states "Not Found".

No
The device is indicated for controlling surface bleeding, which is a supportive function by promoting hemostasis rather than treating a disease or health condition.

No.
The device description and intended use indicate that the D-Stat Radial is a hemostatic device used to control surface bleeding, which is a therapeutic function rather than a diagnostic one.

No

The device description clearly outlines physical components including a lyophilized pad, adjustable retention strap, and foam pads, and mentions sterilization and biocompatibility testing, indicating it is a physical medical device, not software-only.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is for the "control of surface bleeding from vascular access sites and percutaneous catheters or tubes." This is a direct therapeutic application on the patient's body to stop bleeding.
  • Device Description: The device is a topical hemostat containing active biological components (thrombin) and providing compression. It is applied externally to the bleeding site.
  • Lack of In Vitro Testing: The description of performance studies focuses on securement force and biocompatibility (cytotoxicity, sensitization, irritation), which are relevant for a device applied to the body. There is no mention of testing biological samples (like blood, urine, etc.) outside of the body to diagnose or monitor a condition.
  • Anatomical Site: The anatomical site is "vascular access sites and percutaneous catheters or tubes (surface bleeding)," which are external sites on the patient.

IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) in vitro (outside the body) to provide information for diagnosis, monitoring, or screening. This device does not perform such a function.

N/A

Intended Use / Indications for Use

The D-Stat Radial Topical Hemostat is applied topically and is indicated for the control of surface bleeding from vascular access sites and percutaneous catheters or tubes.

Product codes

QSX, FRO

Device Description

D-Stat Radial topical hemostat (D-Stat Radial) is a hemostatic band consisting of an application device containing a lyophilized pad consisting of thrombin, sodium carboxylmethylcellulose and calcium chloride in a nonwoven gauze, and an adjustable retention strap and attached foam pads. Hemostasis is achieved by the physiological coagulation-inducing properties of the lyophilized pad combined with the compression delivered by the application device.

The D-Stat Radial has been sterilized with irradiation.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

vascular access sites and percutaneous catheters or tubes.

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

The technological difference between the subject and predicate device has been evaluated through performance and biocompatibility tests to provide evidence of substantial equivalence for D-Stat Radial.

The device performance was verified through the following test:

  • Securement Force .

Device samples passed the following biocompatibility tests performed in accordance with ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by FDA. The D-Stat Radial is considered a surface device that contacts the skin for a limited duration (under 24 hours). The battery of tests included the following:

  • Cytotoxicity ●
  • Sensitization
  • . Irritation

Key Metrics

Not Found

Predicate Device(s)

K050133, D-Stat Radial Hemostatic Band (Vascular Solutions, Inc.)

Reference Device(s)

K092612, D-Stat Radial Rad-Band (Vascular Solutions, Inc.)

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

N/A

0

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. Food & Drug Administration".

February 10, 2023

Vascular Solutions LLC Melissa Sommerfeld Principal Regulatory Product Specialist 6401 Sycamore Court North Maple Grove, Minnesota 55369

Re: K200720

Trade/Device Name: D-Stat Radial Topical Hemostat Regulatory Class: Unclassified Product Code: QSX

Dear Melissa Sommerfeld:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated June 26, 2020. Specifically, FDA is updating this SE Letter because FDA has better categorized your device technology under product code QSX.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Julie Morabito, OHT4: Office of Surgical and Infection Control Devices, 240-402-3839, Julie.Morabito@fda.hhs.gov.

Sincerely,

Julie A. Morabito -S

Julie Morabito, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

1

Image /page/1/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The FDA logo is composed of two distinct elements: the Department of Health and Human Services seal on the left and the FDA acronym followed by the full name of the agency on the right. The seal features a stylized eagle emblem, while the FDA text is presented in a clear, sans-serif font, with "U.S. FOOD & DRUG" in a larger font size above "ADMINISTRATION".

June 26, 2020

Vascular Solutions LLC Melissa Sommerfeld Principal Regulatory Product Specialist 6401 Sycamore Ct N Maple Grove, Minnesota 55369

Re: K200720

Trade/Device Name: D-Stat Radial Topical Hemostat Regulatory Class: Unclassified Product Code: FRO Dated: Mav 28, 2020 Received: May 29, 2020

Dear Melissa Sommerfeld:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

2

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Anjana Jain -S

Anjana Jain, Ph.D. Acting Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

3

Indications for Use

510(k) Number (if known)

K200720

Device Name:

D-Stat Radial Topical Hemostat

Indications for Use (Describe)

The D-Stat Radial Topical Hemostat is applied topically and is indicated for the control of surface bleeding from vascular access sites and percutaneous catheters or tubes.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

4

510(k) Summary

[As required by 21 CFR 807.92]

Date Prepared: June 26, 2020

510(k) Number: K200720

Submitter's Name / Contact Person

Manufacturer Vascular Solutions LLC 6464 Sycamore Court North Minneapolis, MN 55369 USA Establishment Registration # 2134812 Contact Person Melissa Sommerfeld Principal Regulatory Product Specialist Tel: 763-656-4300

General Information

Trade NameD-Stat Radial Topical Hemostat
Common / Usual NameD-Stat Radial
Classification NameUnclassified
Regulatory Class:Unclassified
Product Code:FRO
Predicate DeviceK050133, D-Stat Radial Hemostatic Band (Vascular Solutions, Inc.)
Reference DeviceK092612, D-Stat Radial Rad-Band (Vascular Solutions, Inc.)

Device Description

D-Stat Radial topical hemostat (D-Stat Radial) is a hemostatic band consisting of an application device containing a lyophilized pad consisting of thrombin, sodium carboxylmethylcellulose and calcium chloride in a nonwoven gauze, and an adjustable retention strap and attached foam pads. Hemostasis is achieved by the physiological coagulation-inducing properties of the lyophilized pad combined with the compression delivered by the application device.

The D-Stat Radial has been sterilized with irradiation.

Indications for Use

The D-Stat Radial topical hemostat is applied topically and is indicated for the control of surface bleeding from vascular access sites and percutaneous catheters or tubes.

Technological Characteristics Comparison

The key technological difference between the D-Stat Radial and the predicate device is a change to the retention strap material.

Substantial Equivalence and Summarv of Studies

The technological difference between the subject and predicate device has been evaluated through performance and biocompatibility tests to provide evidence of substantial equivalence for D-Stat Radial.

The device performance was verified through the following test:

  • Securement Force .

5

K200720 Page 2 of 2

Device samples passed the following biocompatibility tests performed in accordance with ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by FDA. The D-Stat Radial is considered a surface device that contacts the skin for a limited duration (under 24 hours). The battery of tests included the following:

  • Cytotoxicity ●
  • Sensitization
  • . Irritation

Conclusions

The D-Stat Radial Hemostatic Band is substantially equivalent in both the indications for use and technological characteristics to the predicate device and do not raise new questions of safety or effectiveness.